PE43795A1 - Compuesto neuroprotector - Google Patents
Compuesto neuroprotectorInfo
- Publication number
- PE43795A1 PE43795A1 PE1995259688A PE25968895A PE43795A1 PE 43795 A1 PE43795 A1 PE 43795A1 PE 1995259688 A PE1995259688 A PE 1995259688A PE 25968895 A PE25968895 A PE 25968895A PE 43795 A1 PE43795 A1 PE 43795A1
- Authority
- PE
- Peru
- Prior art keywords
- pct
- sec
- neuroprotector
- compound
- date
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE AL COMPUESTO 3R 4S 3-(4-(4-FLUOROFENIL)-4-HIDROXI-PIPERIDIN-1-IL)-CROMAN-4,7-DIOL, DE FORMULA I, SUS ISOMEROS OPTICOS EN FORMA DE UNA MEZCLA RACEMICA Y SUS ENANTIOMEROS DEXTROGIRATORIOS O LEVOGIRATORIOS EN FORMA INDEPENDIENTE, ASI COMO SUS SALES TAL COMO TARTRATO ETANOLATO HIDRATADO; EL CUAL ES UTIL COMO ANTAGONISTA DE AMINOACIDOS EXCITATORIOS, POR BLOQUEO DEL RECEPTOR AL INTERACTUAR CON EL SITIO DE UNION PARA EL GLUTAMATO, TAL COMO SOBRE EL RECEPTOR IONOTROPICO NMDA (N-METIL-D-ASPARTICO); POR LO QUE PUEDE SER UTIL EN EL TRATAMIENTO DE DESORDENES NEUROLOGICOS, CONVULSIVOS, ANSIOLITICOS, PSICOTICOS, Y EN EL TRATAMIENTO DE MIGRANA Y COMO RELAJANTE MUSCULAR
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18947994A | 1994-01-31 | 1994-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE43795A1 true PE43795A1 (es) | 1995-12-09 |
Family
ID=22697514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1995259688A PE43795A1 (es) | 1994-01-31 | 1995-01-18 | Compuesto neuroprotector |
Country Status (27)
Country | Link |
---|---|
US (1) | US5744483A (es) |
EP (1) | EP0741724B1 (es) |
JP (1) | JP2866743B2 (es) |
CN (1) | CN1048247C (es) |
AT (1) | ATE183184T1 (es) |
AU (1) | AU684568B2 (es) |
BR (2) | BR9408506A (es) |
CA (1) | CA2182101C (es) |
CO (1) | CO4230161A1 (es) |
CZ (1) | CZ286757B6 (es) |
DE (1) | DE69420053T2 (es) |
DK (1) | DK0741724T3 (es) |
EG (1) | EG20672A (es) |
ES (1) | ES2134361T3 (es) |
FI (1) | FI113769B (es) |
GR (1) | GR3031356T3 (es) |
HU (1) | HU221633B1 (es) |
IL (1) | IL112415A (es) |
MY (1) | MY111623A (es) |
NO (1) | NO309190B1 (es) |
NZ (1) | NZ275151A (es) |
PE (1) | PE43795A1 (es) |
PL (1) | PL179448B1 (es) |
RU (1) | RU2126404C1 (es) |
TW (1) | TW449591B (es) |
WO (1) | WO1995020587A1 (es) |
ZA (1) | ZA95692B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0859773A1 (en) * | 1995-09-15 | 1998-08-26 | Pfizer Inc. | Phenol derivatives with pharmaceutical activity |
TW498067B (en) * | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
EP1674087A1 (en) | 2000-10-02 | 2006-06-28 | Pfizer Products Inc. | Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists |
ZA200108038B (en) * | 2000-10-02 | 2003-04-01 | Pfizer Prod Inc | Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists. |
SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
CA2547283C (en) * | 2003-11-26 | 2010-11-09 | Pfizer Products Inc. | Aminopyrazole derivatives as gsk-3 inhibitors |
JP2009514828A (ja) | 2005-11-03 | 2009-04-09 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht6阻害剤としてのアリールスルホニルクロマン類、タンパク質キナーゼ阻害剤としてのインドリルマレイミド誘導体 |
CN102702044A (zh) * | 2006-01-20 | 2012-10-03 | 先灵公司 | 作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物 |
EP2522647B1 (en) * | 2011-05-10 | 2014-04-30 | DSM IP Assets B.V. | Process of separating chiral isomers of chroman compounds and their derivatives and precursors |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3294804A (en) * | 1961-01-27 | 1966-12-27 | Sterling Drug Inc | 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine |
FR5733M (es) * | 1966-09-27 | 1968-01-22 | ||
GB1495526A (en) * | 1974-05-31 | 1977-12-21 | Beecham Group Ltd | Chroman derivatives |
US4016281A (en) * | 1975-02-22 | 1977-04-05 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Tetralone and indanone compounds |
US4082755A (en) * | 1977-02-14 | 1978-04-04 | Janssen Pharmaceutica N.V. | 1-[(Diarylmethyl)aminoalkyl]piperidimes |
WO1980000152A1 (en) * | 1978-07-03 | 1980-02-07 | Sandoz Ag | 3-aminopropoxy-aryl derivates,preparation and use thereof |
US4358456A (en) * | 1980-05-03 | 1982-11-09 | John Wyeth & Brother Limited | Antipsychotic piperidinomethyl-indole derivatives |
DE3045688A1 (de) * | 1980-12-04 | 1982-07-08 | C.H. Boehringer Sohn, 6507 Ingelheim | Neue 8-arylalkyl-3-phenyl-3-nortropanole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung |
GB2107706A (en) * | 1981-09-25 | 1983-05-05 | Beecham Group Plc | Benzopyrans |
EP0093534A1 (en) * | 1982-04-28 | 1983-11-09 | Beecham Group Plc | Novel chromanols |
GB8308064D0 (en) * | 1983-03-24 | 1983-05-05 | Beecham Group Plc | Active compounds |
FR2581993B1 (fr) * | 1985-05-14 | 1988-03-18 | Synthelabo | Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique |
US4957928A (en) * | 1986-06-26 | 1990-09-18 | Ciba-Geigy Corporation | Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds |
US4968678A (en) * | 1988-02-19 | 1990-11-06 | Eli Lilly And Company | Tetrazole excitatory amino acid receptor antagonists |
FR2640266B2 (fr) * | 1988-07-12 | 1992-07-10 | Synthelabo | Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique |
US4968878A (en) * | 1989-02-07 | 1990-11-06 | Transitions Research Corporation | Dual bumper-light curtain obstacle detection sensor |
US4902695A (en) * | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
SK279476B6 (sk) * | 1989-05-17 | 1998-11-04 | Pfizer | Deriváty 2-piperidino a 2-pyrolidino-1-alkanolov a |
HU222726B1 (hu) * | 1990-02-06 | 2003-09-29 | Pfizer, Inc., | Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények |
US5192751A (en) * | 1992-07-24 | 1993-03-09 | Eli Lilly And Company | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
-
1994
- 1994-11-21 JP JP7519959A patent/JP2866743B2/ja not_active Expired - Lifetime
- 1994-11-21 DE DE69420053T patent/DE69420053T2/de not_active Expired - Fee Related
- 1994-11-21 CZ CZ19962256A patent/CZ286757B6/cs not_active IP Right Cessation
- 1994-11-21 EP EP94931668A patent/EP0741724B1/en not_active Expired - Lifetime
- 1994-11-21 RU RU96117381A patent/RU2126404C1/ru not_active IP Right Cessation
- 1994-11-21 DK DK94931668T patent/DK0741724T3/da active
- 1994-11-21 AU AU80663/94A patent/AU684568B2/en not_active Ceased
- 1994-11-21 CA CA002182101A patent/CA2182101C/en not_active Expired - Fee Related
- 1994-11-21 US US08/687,542 patent/US5744483A/en not_active Expired - Fee Related
- 1994-11-21 WO PCT/IB1994/000365 patent/WO1995020587A1/en active IP Right Grant
- 1994-11-21 ES ES94931668T patent/ES2134361T3/es not_active Expired - Lifetime
- 1994-11-21 CN CN94194940A patent/CN1048247C/zh not_active Expired - Fee Related
- 1994-11-21 NZ NZ275151A patent/NZ275151A/en unknown
- 1994-11-21 HU HU9602100A patent/HU221633B1/hu not_active IP Right Cessation
- 1994-11-21 PL PL94315681A patent/PL179448B1/pl unknown
- 1994-11-21 BR BR9408506A patent/BR9408506A/pt not_active Application Discontinuation
- 1994-11-21 AT AT94931668T patent/ATE183184T1/de not_active IP Right Cessation
- 1994-11-22 TW TW083110873A patent/TW449591B/zh active
-
1995
- 1995-01-18 PE PE1995259688A patent/PE43795A1/es not_active Application Discontinuation
- 1995-01-23 IL IL11241595A patent/IL112415A/xx not_active IP Right Cessation
- 1995-01-27 MY MYPI95000224A patent/MY111623A/en unknown
- 1995-01-27 CO CO95003001A patent/CO4230161A1/es unknown
- 1995-01-28 EG EG6795A patent/EG20672A/xx active
- 1995-01-30 ZA ZA95692A patent/ZA95692B/xx unknown
- 1995-01-30 FI FI950403A patent/FI113769B/fi not_active IP Right Cessation
- 1995-01-30 BR BR9500380A patent/BR9500380A/pt not_active IP Right Cessation
-
1996
- 1996-07-30 NO NO963186A patent/NO309190B1/no unknown
-
1999
- 1999-09-29 GR GR990402449T patent/GR3031356T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA49869C2 (uk) | Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора | |
ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
ATE206611T1 (de) | Verwendung von mangiferin oder seinen derivaten zur kosmetischen anwendung | |
FI964332A (fi) | Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen | |
DK0946162T3 (da) | Anvendelse af p-aminophenol-derivater til fremstilling af farmaceutiske præparater, som er nyttige til behandlingen af neurodegenerative sygdomme | |
PE43795A1 (es) | Compuesto neuroprotector | |
RU94044356A (ru) | Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с | |
NO20091111L (no) | Anvendelse av R(+)-alfa-(2,3-dimetoksyfenyl)-l-[2-(4-fluorfenyl)etyl]-4-piperidin-metanol for behandling av sovnforstyrrelser | |
EP0653936A1 (en) | USE OF 2- (4- (4-CHLOROPHENYL) CYCLOHEXYL] -3-HYDROXY-1,4-NAPHTOQUINONE IN THE TREATMENT OF CANCER. | |
RU94044487A (ru) | Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |